These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G Retina; 2006; 26(5):495-511. PubMed ID: 16770255 [TBL] [Abstract][Full Text] [Related]
24. Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab--a randomized controlled trial. Gharbiya M; Giustolisi R; Allievi F; Fantozzi N; Mazzeo L; Scavella V; Gabrieli CB Am J Ophthalmol; 2010 Mar; 149(3):458-64.e1. PubMed ID: 20172072 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML Retina; 2007; 27(4):439-44. PubMed ID: 17420695 [TBL] [Abstract][Full Text] [Related]
26. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration]. Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687 [TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results. Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116 [TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab for treatment of myopic choroidal neovascularization: the second year of a prospective study. Gharbiya M; Allievi F; Conflitti S; Esposito M; Scavella V; Moramarco A; Cruciani F Clin Ter; 2010; 161(3):e87-93. PubMed ID: 20589348 [TBL] [Abstract][Full Text] [Related]
29. Intravitreal bevacizumab for the treatment of choroidal neovascularization secondary to angioid streaks: one year of follow-up. El Matri L; Kort F; Bouraoui R; Karim B; Chebil A; Chaker N Acta Ophthalmol; 2011 Nov; 89(7):641-6. PubMed ID: 21155980 [TBL] [Abstract][Full Text] [Related]
30. A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. Algvere PV; Steén B; Seregard S; Kvanta A Acta Ophthalmol; 2008 Aug; 86(5):482-9. PubMed ID: 18162062 [TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: long-term results. Julián K; Terrada C; Fardeau C; Cassoux N; Français C; LeHoang P; Bodaghi B Acta Ophthalmol; 2011 Mar; 89(2):179-84. PubMed ID: 21348964 [TBL] [Abstract][Full Text] [Related]
32. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization. Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271 [TBL] [Abstract][Full Text] [Related]
33. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194 [TBL] [Abstract][Full Text] [Related]
34. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Lai TY; Chan WM; Liu DT; Lam DS Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555 [TBL] [Abstract][Full Text] [Related]